HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Laurent Bélec Selected Research

COVID-19

6/2022Analytical performance of the point-of-care BIOSYNEX COVID-19 Ag BSS for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swabs: a prospective field evaluation during the COVID-19 third wave in France.
1/2022Circulating Ubiquitous RNA, A Highly Predictive and Prognostic Biomarker in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients.
1/2022Severe relapse of SARS-CoV-2 infection in a kidney transplant recipient with negative nasopharyngeal SARS-CoV-2 RT-PCR after rituximab.
11/2021Evaluation of the Practicability of Biosynex Antigen Self-Test COVID-19 AG+ for the Detection of SARS-CoV-2 Nucleocapsid Protein from Self-Collected Nasal Mid-Turbinate Secretions in the General Public in France.
11/2021Highly Sensitive Quantification of Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Sheds Light on its Potential Clinical Value.
5/2021Analytical performances of the point-of-care SIENNA™ COVID-19 Antigen Rapid Test for the detection of SARS-CoV-2 nucleocapsid protein in nasopharyngeal swabs: A prospective evaluation during the COVID-19 second wave in France.
1/2021Unexpected high frequency of unspecific reactivities by testing pre-epidemic blood specimens from Europe and Africa with SARS-CoV-2 IgG-IgM antibody rapid tests points to IgM as the Achilles heel.
1/2021Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient.
1/2021Analytical performances of five SARS-CoV-2 whole-blood finger-stick IgG-IgM combined antibody rapid tests.
11/2020Unexpected diagnosis of COVID-19-associated disorders by SARS-CoV-2-specific serology.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Laurent Bélec Research Topics

Disease

17Infections
01/2022 - 01/2002
11COVID-19
06/2022 - 01/2020
5Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2023 - 01/2019
4Virus Diseases (Viral Diseases)
01/2021 - 01/2005
4Acquired Immunodeficiency Syndrome (AIDS)
05/2020 - 01/2002
3Papillomavirus Infections
10/2023 - 01/2020
3Sexually Transmitted Diseases (Sexually Transmitted Disease)
01/2018 - 09/2002
3HIV Infections (HIV Infection)
07/2011 - 03/2004
2Neoplasm Metastasis (Metastasis)
01/2023 - 01/2023
2Carcinoma (Carcinomatosis)
01/2021 - 11/2005
2Hepatitis C
05/2018 - 01/2018
2Herpes Genitalis (Genital Herpes)
05/2014 - 07/2009
2Neoplasms (Cancer)
11/2009 - 12/2007
2HIV Seropositivity
05/2003 - 09/2002
1Communicable Diseases (Infectious Diseases)
01/2022
1COVID-19 rebound
01/2022
1Fever (Fevers)
01/2022
1Human Influenza (Influenza)
08/2021
1B-Cell Lymphoma (Lymphoma, B Cell)
01/2021
1Cryptococcal Meningitis
01/2020
1Squamous Cell Carcinoma of Head and Neck
01/2020
1Herpes Zoster
01/2020
1Opportunistic Infections (Opportunistic Infection)
01/2020
1Oropharyngeal Neoplasms
01/2020
1Kaposi Sarcoma (Kaposi's Sarcoma)
01/2020
1Disease Progression
01/2020
1Head and Neck Neoplasms (Head and Neck Cancer)
01/2019
1Persistent Infection
01/2018
1Tetanus
01/2017
1Whooping Cough (Pertussis)
01/2017
1Poliomyelitis (Polio)
01/2017
1Diphtheria
01/2017
1Syphilis
12/2013
1Diabetes Complications
05/2011
1Hyperglycemia
05/2011
1Sarcoma (Soft Tissue Sarcoma)
11/2009
1Neuroblastoma
11/2009
1Glioblastoma (Glioblastoma Multiforme)
11/2009
1Ulcer
07/2009
1Respiratory Tract Infections (Respiratory Tract Infection)
01/2005
1Herpes Simplex
06/2003
1Progressive Multifocal Leukoencephalopathy
01/2002

Drug/Important Bio-Agent (IBA)

13DNA (Deoxyribonucleic Acid)IBA
10/2023 - 01/2002
7RNA (Ribonucleic Acid)IBA
01/2022 - 06/2003
7AntibodiesIBA
05/2018 - 05/2003
5VaccinesIBA
10/2023 - 04/2005
5Immunoglobulin G (IgG)IBA
01/2021 - 01/2020
4AntigensIBA
06/2022 - 03/2004
4Biomarkers (Surrogate Marker)IBA
01/2022 - 01/2020
4Hepatitis B Surface Antigens (HBsAg)FDA Link
01/2021 - 01/2018
3Nucleocapsid ProteinsIBA
06/2022 - 05/2021
3Proteins (Proteins, Gene)FDA Link
06/2022 - 12/2007
3Immunoglobulin M (IgM)IBA
01/2021 - 01/2020
2Nucleic AcidsIBA
11/2020 - 01/2005
2Anti-Infective Agents (Microbicides)IBA
07/2011 - 06/2010
2Complement System Proteins (Complement)IBA
06/2010 - 01/2007
1Ribonuclease P (RNase P)IBA
01/2022
1Rituximab (Mabthera)FDA Link
01/2022
1CytokinesIBA
11/2021
1Monoclonal AntibodiesIBA
01/2021
1Formaldehyde (Formol)FDA Link
01/2019
1ParaffinIBA
01/2019
1NucleotidesIBA
01/2019
1Surface Antigens (Surface Antigen)IBA
05/2018
1Tramadol (K315)FDA LinkGeneric
12/2017
1calcium phosphateIBA
01/2017
1Antiviral Agents (Antivirals)IBA
05/2014
1Protease Inhibitors (Protease Inhibitor)IBA
05/2011
1Advanced Glycation End ProductsIBA
05/2011
1ProdrugsIBA
11/2009
1nicotinate phosphoribosyltransferaseIBA
11/2009
11- (2- (2- (2- (2- methoxyethoxy)ethoxy)ethoxy)ethoxycarbonyloxymethyl)- 4- (N'- cyano- N''- (6- (4- chlorophenoxy)hexyl)- N- guanidino)pyridiniumIBA
11/2009
1N- (6- chlorophenoxyhexyl)- N''- cyano- N''- 4- pyridylguanidine (CHS 828)IBA
11/2009
1NAD (NADH)IBA
11/2009
1Messenger RNA (mRNA)IBA
11/2009
1Acyclovir (Aciclovir)FDA LinkGeneric
07/2009
1Monoterpenes (Monoterpenoids)IBA
06/2008
1ZincIBA
06/2008
1Chemokine CCL5IBA
01/2007
1DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA
01/2007
1Combined VaccinesIBA
11/2005
1Indicators and Reagents (Reagents)IBA
04/2005
1dermaseptinIBA
04/2005
1Local Anti-Infective Agents (Antiseptics)IBA
04/2005
1Antimicrobial PeptidesIBA
04/2005
1Peptides (Polypeptides)IBA
02/2004
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
02/2004
1Codon (Codons)IBA
02/2004

Therapy/Procedure

6Therapeutics
01/2022 - 07/2009
1Self-Testing
01/2020
1Highly Active Antiretroviral Therapy (HAART)
01/2020
1Condoms (Condom)
09/2002